Literature DB >> 8448244

Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.

G Lambertenghi-Deliliers1, C Annaloro, A Oriani, D Soligo, E Pozzoli, E E Polli.   

Abstract

Bone marrow biopsy (BMB) has aroused growing interest as a possible aid in the diagnostic and prognostic evaluation of myelodysplastic syndromes (MDS). Previous reports have pointed out that MDS patients with blastic aggregates or severe bone marrow (BM) fibrosis are characterized by a worse clinical outcome. BMBs of 106 MDS patients were retrospectively reviewed, and relationships among the different histological parameters as well as clinicopathological correlations were looked for. Three patterns of BM blastic infiltration ("diffuse," "cluster," and "large") were recognized. Overt leukemic transformation and overall survival were selected as prognostic end points. BM infiltration was "diffuse" in 18, "cluster" in 48, and "large" in 40 cases. RAEB-t patients accounted for about half of the "large" cases, and none had a "diffuse" pattern (p < 0.01). Nineteen patients showed extensive BM fibrosis; most of them were characterized by "cluster" blastic infiltration and megakaryocyte hyperplasia. Leukemic transformation occurred in 67% of "large" cases (p< 0.001) and in none of the "cluster" cases with severe BM fibrosis (p < 0.01); however, survival was equally poor in these two groups because of early leukemic transformation (large cases) and BM failure (cluster cases). The FAB classification did not significantly correlate with prognosis. Patients with "cluster" BM infiltration and severe fibrosis can be regarded as a true separate MDS subset characterized by unique clinicopathological and prognostic features. Because of the subacute clinical behavior of most cases, and the poor performance status of many elderly patients, there is still controversy as to the best therapeutic approach in MDS. Histological analysis allowed two groups of MDS patients to be identified, both characterized by poor life expectancy, who could benefit from early aggressive chemotherapy.

Entities:  

Mesh:

Year:  1993        PMID: 8448244     DOI: 10.1007/bf01695890

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  28 in total

1.  Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens.

Authors:  J Thiele; H Quitmann; S Wagner; R Fischer
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

Review 2.  The myelodysplastic syndrome--a practical guide.

Authors:  T J Hamblin; D G Oscier
Journal:  Hematol Oncol       Date:  1987 Jan-Mar       Impact factor: 5.271

3.  Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases.

Authors:  S García; M A Sanz; V Amigo; P Colomina; M D Carrera; J I Lorenzo; G F Sanz
Journal:  Am J Hematol       Date:  1988-03       Impact factor: 10.047

4.  Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity.

Authors:  G Lambertenghi-Deliliers; A Orazi; R Luksch; C Annaloro; D Soligo
Journal:  Br J Haematol       Date:  1991-06       Impact factor: 6.998

5.  Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis.

Authors:  K Ohyashiki; I Sasao; J H Ohyashiki; T Murakami; A Iwabuchi; T Tauchi; M Saito; S Nakazawa; H Serizawa; Y Ebihara
Journal:  Cancer       Date:  1991-07-01       Impact factor: 6.860

6.  Myelodysplastic syndromes. A multiparametric study of prognostic factors in 336 patients.

Authors:  B Coiffier; P Adeleine; O Gentilhomme; P Felman; D Treille-Ritouet; P A Bryon
Journal:  Cancer       Date:  1987-12-15       Impact factor: 6.860

7.  Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemia.

Authors:  D J Weisdorf; M M Oken; G J Johnson; R E Rydell
Journal:  Br J Haematol       Date:  1983-12       Impact factor: 6.998

8.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

9.  Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS.

Authors:  G Tricot; C De Wolf-Peeters; R Vlietinck; R L Verwilghen
Journal:  Br J Haematol       Date:  1984-10       Impact factor: 6.998

10.  Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors.

Authors:  A Ríos; M C Cañizo; M A Sanz; T Vallespí; G Sanz; M Torrabadella; F Gomis; C Ruiz; J F San Miguel
Journal:  Br J Haematol       Date:  1990-05       Impact factor: 6.998

View more
  4 in total

1.  Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.

Authors:  Nicolaus Kröger; Tatjana Zabelina; Anja van Biezen; Ronald Brand; Dietger Niederwieser; Rodrigo Martino; Zi Yi Lim; Francesco Onida; Christoph Schmid; Laurent Garderet; Marie Robin; Michael van Gelder; Reinhard Marks; Argiris Symeonidis; Guido Kobbe; Theo de Witte
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Comparison of scoring systems in primary myelodysplastic syndromes.

Authors:  H Maschek; R Gutzmer; H Choritz; A Georgii
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

3.  Myelodysplastic syndrome with myelofibrosis transformed to a precursor B-cell acute lymphoblastic leukemia: a case report with review of the literature.

Authors:  Ayed A Algarni; Mojtaba Akhtari; Kai Fu
Journal:  Case Rep Hematol       Date:  2012-03-29

4.  Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.

Authors:  Fernando Ramos; Cristina Robledo; Francisco Miguel Izquierdo-García; Dimas Suárez-Vilela; Rocío Benito; Marta Fuertes; Andrés Insunza; Eva Barragán; Mónica Del Rey; José María García-Ruiz de Morales; Mar Tormo; Eduardo Salido; Lurdes Zamora; Carmen Pedro; Javier Sánchez-Del-Real; María Díez-Campelo; Consuelo Del Cañizo; Guillermo F Sanz; Jesús María Hernández-Rivas
Journal:  Oncotarget       Date:  2016-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.